Epstein-Barr virus: exploiting the immune system (original) (raw)
Chen, F. et al. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol.69, 3752–3758 (1995). CASPubMedPubMed Central Google Scholar
Tierney, R. J., Steven, N., Young, L. S. & Rickinson, A. B. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol.68, 7374–7385 (1994). CASPubMedPubMed Central Google Scholar
Qu, L. & Rowe, D. T. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J. Virol.66, 3715–3724 (1992). CASPubMedPubMed Central Google Scholar
Babcock, G. J., Decker, L. L., Freeman, R. B. & Thorley-Lawson, D. A. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J. Exp. Med.190, 567–576 (1999). CASPubMedPubMed Central Google Scholar
Joseph, A. M., Babcock, G. J. & Thorley-Lawson, D. A. EBV persistence involves strict selection of latently infected B cells. J. Immunol.165, 2975–2981 (2000). CASPubMed Google Scholar
Babcock, G. J., Decker, L. L., Volk, M. & Thorley-Lawson, D. A. EBV persistence in memory B cells in vivo. Immunity9, 395–404 (1998). CASPubMed Google Scholar
Miyashita, E. M., Yang, B., Babcock, G. J. & Thorley-Lawson, D. A. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol.71, 4882–4891 (1997). CASPubMedPubMed Central Google Scholar
Henle, W. & Henle, G. in The Epstein-Barr Virus (eds Epstein, M. A. & Achong, B. G.) 61–78 (Springer–Verlag, Berlin, 1979). Google Scholar
Khan, G., Miyashita, E. M., Yang, B., Babcock, G. J. & Thorley-Lawson, D. A. Is EBV persistence in vivo a model for B cell homeostasis? Immunity5, 173–179 (1996). CASPubMed Google Scholar
Yao, Q. Y., Rickinson, A. B. & Epstein, M. A. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int. J. Cancer35, 35–42 (1985). CASPubMed Google Scholar
Tan, L. C. et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J. Immunol.162, 1827–1835 (1999). CASPubMed Google Scholar
Coffey, A. J. et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nature Genet.20, 129–135 (1998). CASPubMed Google Scholar
Sayos, J. et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature395, 462–469 (1998). CASPubMed Google Scholar
Hamilton, J. K. et al. X-linked lymphoproliferative syndrome registry report. J. Pediatr.96, 669–673 (1980). CASPubMed Google Scholar
Purtilo, D. T., Cassel, C. K., Yang, J. P. & Harper, R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet1, 935–940 (1975). ArticleCASPubMed Google Scholar
Pope, J. H., Horne, M. K. & Scott, W. Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int. J. Cancer3, 857–866 (1968). CASPubMed Google Scholar
Aman, P., Ehlin-Henriksson, B. & Klein, G. Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J. Exp. Med.159, 208–220 (1984). CASPubMed Google Scholar
Thorley-Lawson, D. A. & Mann, K. P. Early events in Epstein-Barr virus infection provide a model for B cell activation. J. Exp. Med.162, 45–59 (1985). CASPubMed Google Scholar
Rickinson, A. B. & Kieff, E. in Virology 3rd edn Vol. 2 (eds Fields, B. N., Knipe, D. M., & Howley, P. M.) 2397–2446 (Lippincott–Raven, Philadelphia, 1996). Google Scholar
Brooks, L., Yao, Q. Y., Rickinson, A. B. & Young, L. S. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol.66, 2689–2697 (1992). CASPubMedPubMed Central Google Scholar
Babcock, J. G., Hochberg, D. & Thorley-Lawson, A. D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity13, 497–506 (2000). CASPubMed Google Scholar
Babcock, G. J. & Thorley-Lawson, D. A. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc. Natl Acad. Sci. USA97, 12250–12255 (2000). CASPubMedPubMed Central Google Scholar
Thorley-Lawson, D. A. & Babcock, G. J. A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci.65, 1433–1453 (1999). CASPubMed Google Scholar
Fahraeus, R. et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int. J. Cancer42, 329–338 (1988). CASPubMed Google Scholar
Yates, J. L., Warren, N. & Sugden, B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature313, 812–815 (1985). CASPubMed Google Scholar
Caldwell, R. G., Wilson, J. B., Anderson, S. J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity9, 405–411 (1998). CASPubMed Google Scholar
Gires, O. et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J.16, 6131–6140 (1997). CASPubMedPubMed Central Google Scholar
MacLennan, I. C. Germinal centers. Annu. Rev. Immunol.12, 117–139 (1994). CASPubMed Google Scholar
Liu, Y. J. et al. Mechanism of antigen-driven selection in germinal centres. Nature342, 929–931 (1989). CASPubMed Google Scholar
Liu, Y. J. & Arpin, C. Germinal center development. Immunol. Rev.156, 111–126 (1997). CASPubMed Google Scholar
Mosialos, G. et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell80, 389–399 (1995). CASPubMed Google Scholar
Inoue, J. et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp. Cell Res.254, 14–24 (2000). CASPubMed Google Scholar
Baker, S. J. & Reddy, E. P. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene12, 1–9 (1996). CASPubMed Google Scholar
Banchereau, J. et al. The CD40 antigen and its ligand. Annu. Rev. Immunol.12, 881–922 (1994). CASPubMed Google Scholar
Kilger, E., Kieser, A., Baumann, M. & Hammerschmidt, W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J.17, 1700–1709 (1998). CASPubMedPubMed Central Google Scholar
Zimber-Strobl, U. et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J.15, 7070–7078 (1996). CASPubMedPubMed Central Google Scholar
Beaufils, P., Choquet, D., Mamoun, R. Z. & Malissen, B. The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein-Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events. EMBO J.12, 5105–5112 (1993). CASPubMedPubMed Central Google Scholar
Miller, C. L. et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity2, 155–166 (1995). CASPubMed Google Scholar
Kurosaki, T. Genetic analysis of B cell antigen receptor signaling. Annu. Rev. Immunol.17, 555–592 (1999). CASPubMed Google Scholar
Maruyama, M., Lam, K. P. & Rajewsky, K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature407, 636–642 (2000). CASPubMed Google Scholar
Lam, K. P., Kuhn, R. & Rajewsky, K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell90, 1073–1083 (1997). CASPubMed Google Scholar
Hoagland, R. J. The transmission of infectious mononucleosis. Am. J. Med. Sci.229, 262–272 (1955). CASPubMed Google Scholar
Gordadze, A. V. et al. Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus. J. Virol.75, 5899–5912 (2001). CASPubMedPubMed Central Google Scholar
Joseph, A. M., Babcock, G. J. & Thorley-Lawson, D. A. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J. Virol.74, 9964–9971 (2000). CASPubMedPubMed Central Google Scholar
Ling, P. D., Hsieh, J. J., Ruf, I. K., Rawlins, D. R. & Hayward, S. D. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1. J. Virol.68, 5375–5383 (1994). CASPubMedPubMed Central Google Scholar
Ansel, K. M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature406, 309–314 (2000). CASPubMed Google Scholar
Polack, A. et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)- transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc. Natl Acad. Sci. USA93, 10411–10416 (1996). CASPubMedPubMed Central Google Scholar
Hofelmayr, H., Strobl, L. J., Marschall, G., Bornkamm, G. W. & Zimber-Strobl, U. Activated Notch1 can transiently substitute for EBNA2 in the maintenance of proliferation of LMP1-expressing immortalized B cells. J. Virol.75, 2033–2040 (2001). CASPubMedPubMed Central Google Scholar
Uchida, J. et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science286, 300–303 (1999). CASPubMed Google Scholar
Araujo, I. et al. Frequent expansion of Epstein-Barr virus (EBV) infected cells in germinal centres of tonsils from an area with a high incidence of EBV-associated lymphoma. J. Pathol.187, 326–330(1999). CASPubMed Google Scholar
Anagnostopoulos, I., Hummel, M., Kreschel, C. & Stein, H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood85, 744–750 (1995). CASPubMed Google Scholar
Kurth, J. et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity13, 485–495 (2000). CASPubMed Google Scholar
Selin, L. K., Varga, S. M., Wong, I. C. & Welsh, R. M. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J. Exp. Med.188, 1705–1715 (1998). CASPubMedPubMed Central Google Scholar
Khanna, R., Moss, D. J. & Burrows, S. R. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev.170, 49–64 (1999). CASPubMed Google Scholar
Carbone, A., Tirelli, U., Gloghini, A., Volpe, R. & Boiocchi, M. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J. Clin. Oncol.11, 1674–1681 (1993). CASPubMed Google Scholar
Thomas, J. A. et al. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation49, 944–953 (1990). CASPubMed Google Scholar
Rooney, C. M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet345, 9–13 (1995). CASPubMed Google Scholar
Wang, D., Liebowitz, D. & Kieff, E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell43, 831–840 (1985). CASPubMed Google Scholar
Oudejans, J. J. et al. Expression of Epstein-Barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV. J. Clin. Pathol.49, 897–902 (1996). CASPubMedPubMed Central Google Scholar
Pallesen, G., Hamilton-Dutoit, S. J., Rowe, M. & Young, L. S. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet337, 320–322 (1991). CASPubMed Google Scholar
Herbst, H. et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed–Sternberg cells. Proc. Natl Acad. Sci. USA88, 4766–4770 (1991). CASPubMedPubMed Central Google Scholar
Niedobitek, G. et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood90, 1664–1672 (1997). CASPubMed Google Scholar
Hammarskjold, M. L. & Simurda, M. C. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J. Virol.66, 6496–6501 (1992). CASPubMedPubMed Central Google Scholar
Brandtzaeg, P., Farstad I. N. & Haraldsen, G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol. Today.20, 267–277 (1999). CASPubMed Google Scholar
Klein, U., Rajewsky, K. & Kuppers, R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med.188, 1679–1689 (1998). CASPubMedPubMed Central Google Scholar
Artavanis-Tsakonas, S., Matsuno, K. & Fortini, M. E. Notch signaling. Science268, 225–232 (1995). CASPubMed Google Scholar
Sullivan, J. L. & Woda, B. A. X-linked lymphoproliferative syndrome. Immunodefic. Rev.1, 325–347 (1989). CASPubMed Google Scholar
Callan, M. F. et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med.187, 1395–1402 (1998). CASPubMedPubMed Central Google Scholar
Epstein, M. A., Achong, B. G. & Barr, Y. M. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet1, 702–703 (1964). CASPubMed Google Scholar
Leder, P. in Burkitt's Lymphoma: A Human Cancer Model (eds Lenoir, G. M., O'Conor, G. T. & Olweny, C. L. M.) 341–371 (Oxford Univ. Press, New York, 1985). Google Scholar
Manolov, G. & Manolova, Y. Marker band in one chromosome 14 from Burkitt lymphomas. Nature237, 33–34 (1972). CASPubMed Google Scholar
Gregory, C. D., Rowe, M. & Rickinson, A. B. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol.71, 1481–1495 (1990). CASPubMed Google Scholar
Muir, C. S. Cancer of the head and neck. Nasopharyngeal cancer. Epidemiology and etiology. J. Am. Med. Assoc.220, 393–394 (1972). CAS Google Scholar
Andersson-Anvret, M., Forsby, N., Klein, G. & Henle, W. Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int. J. Cancer20, 486–494 (1977). CASPubMed Google Scholar
Yu, M. C., Huang, T. B. & Henderson, B. E. Diet and nasopharyngeal carcinoma: a case-control study in Guangzhou, China. Int. J. Cancer43, 1077–1082 (1989). CASPubMed Google Scholar
Klein, G. in The Epstein-Barr virus (eds Epstein, M. A. & Achong, B. G.) 340–350 (Springer–Verlag, Berlin, 1979). Google Scholar
Niedobitek, G. The Epstein-Barr virus: a group 1 carcinogen? Virchows Arch.435, 79–86 (1999). CASPubMed Google Scholar
Thorley-Lawson, D. A. in Samter's Immunologic Diseases 6th edn (eds Austen, K. F., Frank, M. M., Atkinson, J. P. & Cantor, H.) 970–985 (Williams and Wilkins, New York, 2001). Google Scholar
Kaiser, C. et al. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J. Virol.73, 4481–4484 (1999). CASPubMedPubMed Central Google Scholar
Parker, G. A. et al. Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene13, 2541–2549 (1996). CASPubMed Google Scholar
Hsing, Y., Hostager, B. S. & Bishop, G. A. Characterization of CD40 signaling determinants regulating nuclear factor-κB activation in B lymphocytes. J. Immunol.159, 4898–4906 (1997). CASPubMed Google Scholar
Hanissian, S. H. & Geha, R. S. JAK3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity6, 379–387 (1997). CASPubMed Google Scholar
Gires, O. et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J.18, 3064–3073 (1999). CASPubMedPubMed Central Google Scholar
Kieser, A. et al. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the _c_-Jun N-terminal kinase cascade. EMBO J.16, 6478–6485 (1997). CASPubMedPubMed Central Google Scholar
Ishida, T. et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J. Biol. Chem.271, 28745–28748 (1996). CASPubMed Google Scholar
Brodeur, S. R., Cheng, G., Baltimore, D. & Thorley-Lawson, D. A. Localization of the major NF-κB activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signalling motifs. J. Biol. Chem.272, 19777–19784 (1997). CASPubMed Google Scholar
Izumi, K. M. & Kieff, E. D. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF- kappaB. Proc. Natl Acad. Sci. USA94, 12592–12597 (1997). CASPubMedPubMed Central Google Scholar
Kieser, A., Kaiser, C. & Hammerschmidt, W. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J.18, 2511–2521 (1999). CASPubMedPubMed Central Google Scholar
Swart, R., Ruf, I. K., Sample, J. & Longnecker, R. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J. Virol.74, 10838–10845 (2000). CASPubMedPubMed Central Google Scholar